Industry Symposium by Bayer
IND 22 - Latest Innovations and a Glimpse into the Future of Contrast-Enhanced MRI
Lectures
1
Latest Innovations and a Glimpse into the Future of Contrast-Enhanced MRI (Complete Session)
60:00Matthias Gutberlet, Leipzig / DE, Carlo Cosimo Quattrocchi, Trento / IT, Markus Berger, Berlin / DE, Sönke Peters, Kiel / DE
Gadolinium-based contrast agents (GBCAs) have been used in over 800 million contrast-enhanced MRI (CE-MRI) applications worldwide in both patient diagnosis and follow-up scans. The unique in-vivo properties of GBCAs have enabled their widespread adoption, providing valuable diagnostic information across a broad range of indications and serving as an effective option for enhancing the MRI signal intensity.
We provide an important update for all those involved in CE-MRI. This session will focus on the latest innovations and ongoing developments in macrocyclic GBCAs. An expert multi-specialty panel will discuss the potential of optimized utilization of contrast agents in the context of international guidelines and patient preferences, setting the scene for the future of CE-MRI.
Gadoquatrane has not been approved in the European Union.
Learning Objectives:
• Understand the important role of GBCAs in MRI during diagnosis and patient follow up
• Explore latest innovations in GBCAs including an update of ongoing clinical development
• Discuss future directions in CE-MRI with the background of international imaging guidelines, environmental sustainability and patient preferences
PP-GD-ALL-0002-1 11.2024
We provide an important update for all those involved in CE-MRI. This session will focus on the latest innovations and ongoing developments in macrocyclic GBCAs. An expert multi-specialty panel will discuss the potential of optimized utilization of contrast agents in the context of international guidelines and patient preferences, setting the scene for the future of CE-MRI.
Gadoquatrane has not been approved in the European Union.
Learning Objectives:
• Understand the important role of GBCAs in MRI during diagnosis and patient follow up
• Explore latest innovations in GBCAs including an update of ongoing clinical development
• Discuss future directions in CE-MRI with the background of international imaging guidelines, environmental sustainability and patient preferences
PP-GD-ALL-0002-1 11.2024
10 min
GBCA use worldwide in clinical practice
Matthias Gutberlet, Leipzig / Germany
10 min
An intent to lower the gadolinium dose for CNS MR imaging in adults
Carlo Cosimo Quattrocchi, Trento / Italy
10 min
Discovery of Bayer’s low dose mGBCA
Markus Berger, Berlin / Germany
10 min
Phase 1 and 2 study results
Sönke Peters, Kiel / Germany
20 min
Panel discussion
Matthias Gutberlet, Leipzig / Germany
Only users with an ECR registration can claim CME credits and the Certificate of Attendance for Free Sessions.
Matthias Gutberlet
Leipzig / GermanyCarlo Cosimo Quattrocchi
Trento / ItalyMarkus Berger
Berlin / GermanySönke Peters
Kiel / Germany
Comments
This commenting area is designed as a platform to ask questions related to the session content. If you have queries concerning the functionality of ESR Connect, please refer to the FAQs.